Precision oncology advances through tumor-agnostic therapies and evolving biomarker testing

Medical experts are highlighting the growing importance of tumor-agnostic precision oncology, which focuses on targeting specific molecular alterations rather than the tumor's location in the body. During a plenary session at Great Debates in Solid Tumors, Dr. Vivek Subbiah of NYU Perlmutter Cancer Center discussed how comprehensive molecular profiling and biomarker interpretation can guide the use of targeted therapies, immunotherapies, and antibody-drug conjugates.

Key actionable biomarkers include NTRK and RET fusions, BRAF V600 mutations, microsatellite instability, and HER2 overexpression. Experts emphasize that clinicians must distinguish between detected molecular alterations and those that are truly actionable and druggable to optimize patient outcomes.

Additionally, researchers are addressing the challenge of tumor evolution. Dr. Brian Corgiat of Ignite Proteomics noted that tumors are dynamic and can change over time, particularly in response to therapeutic pressure. Because surviving cells may develop resistance mechanisms, a tumor's profile during recurrence may differ significantly from its initial state. Experts suggest that cancer testing should be viewed as a snapshot of a specific moment to ensure treatments target currently active proteins.